Allergan Plc (NYSE:AGN) Explodes After FDA Approval Of Natrelle Inspira

-
0
Allergan Plc (NYSE:AGN) Explodes After FDA Approval Of Natrelle Inspira

Allergan Plc (NYSE:AGN) is trading higher in the market early into the New Year, after clinching FDA approval for its breast implant treatment, Natrelle Inspira. The approval goes a long way in providing women undergoing breast reconstruction or augmentation a new cohesive implant option.

Natrelle Inspira Approval

The FDA approval also makes Allergan SoftTouch breast implants the only implant line in the market with three levels of cohesive gel. What this means is that physicians can now meet diverse patient needs depending on breast tissue and desired outcomes according to Chief R&D officer David Nicholson.

“Adding NATRELLE INSPIRA® SoftTouch breast implants to our already robust line of offerings give Allergan the most extensive variety of implants in the industry and provide doctors with a wide range of options, “said Mr. Nicholson.

The new breast implants are approved for reconstruction, which means physicians can use them to replace breast tissue in patients who might have suffered cancer or trauma. Natrelle breast implants can also be used to correct or improve breast reconstruction surgeries.

However, the FDA approval bars women with an active infection anywhere in the body or with existing cancer or precancer from receiving the new implants. Pregnant women or those that are nursing are also advised not to pursue the implants, for obvious reasons. The implants are also approved for women at least 22 years for silicone-filled implants. Saline-filled implants can also be administered to women at least 18 years.

Stock Performance

While the approval is a big win for Allergan, it awaits to be seen if it will have an impact in catapulting the stock higher in the market. For the better part last year the stock was engulfed in a downward trend having tanked to lows of $185 a share before bouncing back as the year ended.

The stock’s immediate resistance currently stands at $220 a share above which the stock could soar to highs of $250 a share. Failure to break above the tight resistance could push the stock lower with immediate support currently at $185 a share.

Allergan stock was up by $6.18 in Tuesday trading session closing the day at highs of $216.19 a share.